Pivotal bioVenture Partners Investment Advisor LLC
Q3 2025 13F-HR Holdings
Net value change ($000)
+11,641
(7.2%)
New positions
1
Sold out positions
3
Turnover %
17.1%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to Q2 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ARQT | 10,242 | 34.5% |
| ZBIO | 9,746 | 129.1% |
| PCVX | 7,005 | 16.5% |
| IMNM | 5,884 | NEW |
| TRVI | 5,231 | 83.4% |
| BIOA | 1,144 | 42.4% |
| RLYB | 387 | 47.6% |
Top Reduces (Value $000, Stocks/ETFs)
| INOZYME PHARMA INC | -17,979 | -100.0% |
| Vigil Neuroscience, Inc. | -4,457 | -100.0% |
| OCS | -4,210 | -9.4% |
| IOBT | -1,201 | -100.0% |
| RXRX | -107 | -3.6% |
| BOLT | -43 | -7.9% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|